Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Current Leases (2021 - 2025)

Historic Current Leases for Indivior Pharmaceuticals (INDV) over the last 5 years, with Q3 2025 value amounting to $10.0 million.

  • Indivior Pharmaceuticals' Current Leases changed N/A to $10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year change of. This contributed to the annual value of $10.0 million for FY2024, which is 1111.11% up from last year.
  • Indivior Pharmaceuticals' Current Leases amounted to $10.0 million in Q3 2025.
  • Indivior Pharmaceuticals' 5-year Current Leases high stood at $11.0 million for Q1 2025, and its period low was $8.0 million during Q4 2021.
  • For the 5-year period, Indivior Pharmaceuticals' Current Leases averaged around $9.6 million, with its median value being $10.0 million (2024).
  • As far as peak fluctuations go, Indivior Pharmaceuticals' Current Leases changed by 0.0% in 2022, and later surged by 1250.0% in 2023.
  • Quarter analysis of 5 years shows Indivior Pharmaceuticals' Current Leases stood at $8.0 million in 2021, then changed by 0.0% to $8.0 million in 2022, then grew by 12.5% to $9.0 million in 2023, then rose by 11.11% to $10.0 million in 2024, then changed by 0.0% to $10.0 million in 2025.
  • Its Current Leases stands at $10.0 million for Q3 2025, versus $11.0 million for Q2 2025 and $11.0 million for Q1 2025.